In the fast-paced world of healthcare, it can take a lot of work to keep up-to-date with the numerous innovations, trends, and opinions that emerge each year.
As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease.
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio
